about
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapyImmunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study.Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group studyPediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studyPhase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupPhase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium studyA phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium reportA phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium ReportPediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group studyValacyclovir and acyclovir pharmacokinetics in immunocompromised children.Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study.Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyNew agents for intrathecal administration.Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study.A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo.Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell linesA phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
P50
Q28237056-2AEEFB14-5D75-4178-8506-65E1681B5CE7Q33297502-C043C9C1-3635-414E-BF7F-3D947F2A603CQ33346436-C7C32C35-BECC-425F-BE54-8BD403EB2920Q33348852-270DA29B-C647-4699-A145-E6C10A7D491CQ33363903-5C06190A-D3E1-4882-9110-284FABED100CQ33364897-6226459A-D816-42CC-90BA-FCD790A20308Q33369385-E0524D03-464C-413A-AF79-7E5C75572EBAQ33370041-2465468D-A476-41F2-AE75-E2CEF261C25BQ33372861-670CE417-078A-4D41-B9C3-1ECBF15B22C7Q33379701-26738760-691D-44D1-A582-AB316C9AA27DQ33387707-2CC704B4-D8BB-43BC-9A7E-EE7268A4E872Q33390459-335FB06C-1E28-459E-9546-09C2AB17182FQ33390536-66C8795E-A6A4-4A39-89F4-162E398F6B3CQ33390957-BC094C60-0C19-4CC5-B4B3-6E9F01A7F09DQ33395853-CBF97C54-C8CF-43AB-A206-00B782678C41Q33398810-1CFB9436-4161-493E-9FF0-468747882864Q33402047-B8198942-629F-4E39-A6F3-B0312CE15496Q33403207-5CFF06D0-1E66-4F28-9D0F-D6BFF48E22F7Q33406813-9E5F91A6-778F-4C1C-8E44-DBD0D7E908D8Q33410758-F25B88F6-9B13-44D0-AEE6-D9BDE9B2E2C8Q33411585-D8270ACE-4C3E-463D-B151-F4CA03430DE1Q33415790-45F1D4A3-E50B-4C94-A250-57AA03371CACQ33418912-A5C01045-EDC8-49CC-ABF9-53F3E910B41DQ33419115-8E55F449-D409-4CE4-8643-74B2B2E39941Q33559116-2AE6F25D-FF8A-4D30-A3BE-3CFB0F1AC26FQ33559444-CFF80C3C-B3F1-4E76-8F21-60F22E3B34F3Q33776931-B79F832E-BCC5-42DC-8CA8-557026A1EE07Q33805149-3A1E1427-D2D6-4535-B6BD-50E81CFF22E1Q33964850-16080FA0-5ACA-40CE-9EC7-B43CEC3E9F78Q33999083-B861F45E-A0A7-4E60-BD62-C8E2B4C20775Q34027888-0FC9546B-FD86-44B6-9736-25540951D4B1Q34132933-FF2745F4-32B4-4CBC-855F-7F0605CF0702Q34193155-DF9F145E-8FFC-4F2A-8503-5A62C9D5DEB5Q34193975-8287749A-0C1E-4514-9F95-1BAAE7F49992Q34287755-E1ABF239-67A7-4E43-AE18-0BA5DC2A45E4Q34332525-1A9B5E02-F009-45A9-B3C9-1D7CAFC96329Q34480521-405E9058-14E4-4323-BBE7-B7C6749F24E9Q34582560-3F990160-7457-4E96-BB09-5A4A52EBD0EAQ34584174-D9734883-AC20-4DE3-A82A-7A4333149623Q34647484-EF9D76FD-D848-4F4D-9284-1B8CA724D0A9
P50
name
Susan M Blaney
@en
Susan M Blaney
@nl
type
label
Susan M Blaney
@en
Susan M Blaney
@nl
prefLabel
Susan M Blaney
@en
Susan M Blaney
@nl